Current methods for detecting cancer biomarkers often lack sensitivity to lifestyle and environmental factors, and can be expensive and time-consuming. This can lead to delays in diagnosis and treatment, particularly for cancers like colorectal cancer that are influenced by environmental factors.

Tagomics offers a multiomic platform that integrates genetic, epigenetic, and fragmentomic profiling to identify disease-associated biomarkers from biological samples. The platform uses advanced bioinformatic and machine learning approaches to provide insights into disease mechanisms and improve diagnostic accuracy. Tagomics' technology enables high-throughput and cost-effective multiomic disease profiling, with low sample input and automation capabilities. The platform is sample-agnostic and designed for reliable and reproducible results.

Multiomic profiling platform integrating genetic, epigenetic, and fragmentomic data

Advanced bioinformatic and machine learning algorithms for biomarker discovery

High-throughput and cost-effective analysis

Low sample input requirements

Automatable workflow

Sample-agnostic design

Reliable and reproducible results

Interlace™ solution for multiomic profiling

The primary target audience includes researchers, clinicians, and pharmaceutical companies focused on early cancer detection and diagnosis, particularly for colorectal and other common cancers.